

## Biosparc advances China–Singapore collaboration with new strategic partnerships

01 December 2025 | News

**Efficient collaboration forms the "foundation" for an international innovation accelerator.**



Biosparc's landmark project in Suzhou Industrial Park reached structural completion. On 20 November 2025 the firm announced a new strategic partnership with True Light PE and ClavystBio, with the goal of strengthening cross-border collaboration in scientific research, translation, and clinical development.

On the same day, Biosparc and the Suzhou Industrial Park Investment Promotion and Operation Co. signed strategic cooperation agreements with three Singapore partners — NCCS (National Cancer Centre Singapore), Essex Bio, and Mirxes — marking a major milestone and laying the foundation for deeper China–Singapore collaboration in the years ahead.

As infrastructure and ecosystem development advance in parallel, Biosparc is building a globally connected innovation platform linking research, clinical resources, and early-stage ventures across both countries.

With the completion of the main project, a new life science innovation platform with international connectivity and capable of supporting cross-border scientific research and clinical collaboration is gradually emerging, and its strategic cooperation ecosystem framework is also taking shape at an accelerated pace.

**Efficient collaboration forms the "foundation" for an international innovation accelerator.**

The Sino-Singapore Life Science Park (Biosparc) project broke ground at the end of 2023, officially commenced construction in April 2024, and completed its main structure topping out in November 2025. While meeting the stringent professional requirements of biomedical facilities regarding floor height, load-bearing capacity, ventilation, and power supply, the project, through a systematic planning of tower corridors, public spaces, and natural landscapes, creates an open and sustainable physical environment for future scientific research collaboration, clinical cooperation, and cross-disciplinary innovation.

The completion of the main structure signifies that international scientific research and cross-border acceleration capabilities have solid infrastructure support, and also reflects the high level of collaborative efficiency among Suzhou Industrial Park, shareholders, and the project team in advancing major life science platforms.

### **Strategic cooperation agreement signed: Building the "China-Singapore International Innovation Corridor"**

As the physical space rapidly takes shape, the construction of Biosparc's ecosystem is also progressing simultaneously.

On the same day, a strategic cooperation signing ceremony was successfully held with Biospark, with signatories including the National Cancer Centre Singapore (NCCS), EssexBio , Mirxes , and Suzhou Industrial Park Investment Promotion and Operation Co., Ltd. (SIPIPB) . The parties will collaborate on research cooperation, clinical trials, early-stage industrialization, and translation, jointly promoting a deeper level of synergy between research, clinical trials, and regulatory oversight.

Furthermore, Biosparc has entered into a strategic partnership with True Light PE and ClavystBio to jointly promote research, clinical, and early-stage industrialization collaborations between innovative entities from China and Singapore within the park. Leveraging their respective resources, the parties will connect research, clinical, and industrialization innovation capabilities in China and Singapore, providing long-term, systematic support for cross-border R&D and project implementation.